These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 19168509)

  • 1. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
    Heymans S; Hirsch E; Anker SD; Aukrust P; Balligand JL; Cohen-Tervaert JW; Drexler H; Filippatos G; Felix SB; Gullestad L; Hilfiker-Kleiner D; Janssens S; Latini R; Neubauer G; Paulus WJ; Pieske B; Ponikowski P; Schroen B; Schultheiss HP; Tschöpe C; Van Bilsen M; Zannad F; McMurray J; Shah AM
    Eur J Heart Fail; 2009 Feb; 11(2):119-29. PubMed ID: 19168509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
    van Bilsen M; Patel HC; Bauersachs J; Böhm M; Borggrefe M; Brutsaert D; Coats AJS; de Boer RA; de Keulenaer GW; Filippatos GS; Floras J; Grassi G; Jankowska EA; Kornet L; Lunde IG; Maack C; Mahfoud F; Pollesello P; Ponikowski P; Ruschitzka F; Sabbah HN; Schultz HD; Seferovic P; Slart RHJA; Taggart P; Tocchetti CG; Van Laake LW; Zannad F; Heymans S; Lyon AR
    Eur J Heart Fail; 2017 Nov; 19(11):1361-1378. PubMed ID: 28949064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can we cure a heart "in flame"? A translational view on inflammation in heart failure.
    Hofmann U; Frantz S
    Basic Res Cardiol; 2013 Jul; 108(4):356. PubMed ID: 23740214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?
    Celis R; Torre-Martinez G; Torre-Amione G
    Curr Opin Cardiol; 2008 May; 23(3):254-60. PubMed ID: 18382215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune modulation in heart failure: past challenges and future hopes.
    Flores-Arredondo JH; García-Rivas G; Torre-Amione G
    Curr Heart Fail Rep; 2011 Mar; 8(1):28-37. PubMed ID: 21221862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies.
    Aimo A; Castiglione V; Borrelli C; Saccaro LF; Franzini M; Masi S; Emdin M; Giannoni A
    Eur J Prev Cardiol; 2020 Mar; 27(5):494-510. PubMed ID: 31412712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapies for heart failure: focus on anti-inflammatory strategies.
    Ramasubbu K; Oliveira G; Torre-Amione G
    Congest Heart Fail; 2006; 12(3):153-9; quiz 160-1. PubMed ID: 16760701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches.
    Gong KZ; Song G; Spiers JP; Kelso EJ; Zhang ZG
    Int J Clin Pract; 2007 Apr; 61(4):611-21. PubMed ID: 17394435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology.
    Jaarsma T; Beattie JM; Ryder M; Rutten FH; McDonagh T; Mohacsi P; Murray SA; Grodzicki T; Bergh I; Metra M; Ekman I; Angermann C; Leventhal M; Pitsis A; Anker SD; Gavazzi A; Ponikowski P; Dickstein K; Delacretaz E; Blue L; Strasser F; McMurray J;
    Eur J Heart Fail; 2009 May; 11(5):433-43. PubMed ID: 19386813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Heart Failure and Inflammation: What Do We Really Know?
    Dick SA; Epelman S
    Circ Res; 2016 Jun; 119(1):159-76. PubMed ID: 27340274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure.
    Hanna A; Frangogiannis NG
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):849-863. PubMed ID: 32902739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation in Heart Failure: JACC State-of-the-Art Review.
    Murphy SP; Kakkar R; McCarthy CP; Januzzi JL
    J Am Coll Cardiol; 2020 Mar; 75(11):1324-1340. PubMed ID: 32192660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure.
    Van Linthout S; Tschöpe C
    Clin Pharmacol Ther; 2019 Dec; 106(6):1198-1208. PubMed ID: 31544235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eschenhagen T; Force T; Ewer MS; de Keulenaer GW; Suter TM; Anker SD; Avkiran M; de Azambuja E; Balligand JL; Brutsaert DL; Condorelli G; Hansen A; Heymans S; Hill JA; Hirsch E; Hilfiker-Kleiner D; Janssens S; de Jong S; Neubauer G; Pieske B; Ponikowski P; Pirmohamed M; Rauchhaus M; Sawyer D; Sugden PH; Wojta J; Zannad F; Shah AM
    Eur J Heart Fail; 2011 Jan; 13(1):1-10. PubMed ID: 21169385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation in chronic heart failure.
    Parish RC; Evans JD
    Ann Pharmacother; 2008 Jul; 42(7):1002-16. PubMed ID: 18477736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
    Zannad F; Garcia AA; Anker SD; Armstrong PW; Calvo G; Cleland JG; Cohn JN; Dickstein K; Domanski MJ; Ekman I; Filippatos GS; Gheorghiade M; Hernandez AF; Jaarsma T; Koglin J; Konstam M; Kupfer S; Maggioni AP; Mebazaa A; Metra M; Nowack C; Pieske B; Piña IL; Pocock SJ; Ponikowski P; Rosano G; Ruilope LM; Ruschitzka F; Severin T; Solomon S; Stein K; Stockbridge NL; Stough WG; Swedberg K; Tavazzi L; Voors AA; Wasserman SM; Woehrle H; Zalewski A; McMurray JJ
    Eur J Heart Fail; 2013 Oct; 15(10):1082-94. PubMed ID: 23787718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design.
    Torre-Amione G; Bourge RC; Colucci WS; Greenberg B; Pratt C; Rouleau JL; Sestier F; Moyé LA; Geddes JA; Nemet AJ; Young JB;
    Can J Cardiol; 2007 Apr; 23(5):369-76. PubMed ID: 17440642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure.
    Sporter RJ; Kim JH; Frishman WH
    Cardiol Rev; 2008; 16(6):280-7. PubMed ID: 18923231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
    Seferovic PM; Ponikowski P; Anker SD; Bauersachs J; Chioncel O; Cleland JGF; de Boer RA; Drexel H; Ben Gal T; Hill L; Jaarsma T; Jankowska EA; Anker MS; Lainscak M; Lewis BS; McDonagh T; Metra M; Milicic D; Mullens W; Piepoli MF; Rosano G; Ruschitzka F; Volterrani M; Voors AA; Filippatos G; Coats AJS
    Eur J Heart Fail; 2019 Oct; 21(10):1169-1186. PubMed ID: 31129923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.